Abstract:Background: Atherosclerosis has been shown to result from chronic inflammation caused by constitutive activation of the pattern recognition receptors (PRR), which are principle effectors of the innate immune system. PRR are present in the endosome or on the cellular membrane and can sense the aberrant release of nucleic acids, which is often a sign of acute or chronic cellular damage. Absent in melanoma 2 (AIM2) is a PRR that is expressed by vascular cells and specializes in detecting cytoplasmic double-stranded DNA (dsDNA). Activation of AIM2 leads eventually to activation of the inflammasome, but the role of AIM2 in vascular disease and atherosclerosis has not been well-studied. Therefore, in this study we took advantage of acute and chronic models of vascular injury to determine the biological role of AIM2 in atherogenesis.Methods and Results: We were able to induce significant release of proinflammatory cytokines in mice through the intravenous injection of a synthetic ligand for AIM2, double-stranded poly dA:dT. This cytokine release was shown to impair reendothelialization of the carotid artery and increase the number of circulating endothelial microparticles (EMP) after acute denudation, compared to treatment with vehicle. We saw an increase in the production of reactive oxygen species in the aorta, the number of circulating EMP, and, most interestingly, atherosclerotic plaque formation in apolipoprotein E-deficient (ApoE−/−) mice when they received continual subcutaneous poly dA:dT, in contrast to vehicle-treated animals. Finally, treatment with poly dA:dT did not impair vascular reendothelialization in AIM2−/− mice compared to vehicle controls in the carotid artery injury model.Conclusion: Overall, our data suggest that AIM2, as a known regulator of the inflammasome, is an active participant in atherogenesis, and highlight the importance of fully understanding the pathological mechanisms involved. It seems to be worth of further exploration as a therapeutic target, and future studies focusing on the effects of AIM2 activation as well as its pharmacological inhibition may reveal promising new therapeutic concepts for the treatment of atherosclerosis.

ATIC-Mediated De Novo Purine Synthesis Protects Endothelial Cells from Disturbed Flow-Induced Injury in Atherosclerosis

Abstract 2074: De Novo Nucleotide Synthesis is Necessary for DNA Damage and Repair in Atheroprone Endothelial Cells

Myeloid-Specific Deletion of Peptidylarginine Deiminase 4 Mitigates Atherosclerosis

Endothelial AIP1 Regulates Vascular Remodeling by Suppressing NADPH Oxidase-2

Abstract 11289: Suppression of <i>De Novo</i> Purine Synthesis Reduces Development and Progression of Pulmonary Hypertension in Rodent Models

Characterization of the Molecular Mechanisms Underlying Increased Ischemic Damage in the Aldehyde Dehydrogenase 2 Genetic Polymorphism Using a Human Induced Pluripotent Stem Cell Model System.

Oxidized phospholipids regulate amino acid metabolism through MTHFD2 to facilitate nucleotide release in endothelial cells

DNMT1 Mediates the Disturbed Flow-Induced Endothelial to Mesenchymal Transition Through Disrupting Β-Alanine and Carnosine Homeostasis.

Purine synthesis suppression reduces the development and progression of pulmonary hypertension in rodent models

IQGAP1 promotes mitochondrial damage and activation of the mtDNA sensor cGAS-STING pathway to induce endothelial cell pyroptosis leading to atherosclerosis

Abstract 461: Enhanced Glycolysis in Endothelial Cells Protects Against Atherosclerosis

AIM2 Stimulation Impairs Reendothelialization and Promotes the Development of Atherosclerosis in Mice

Abstract 5808: Endothelial Cell Polyploidization Induces an Atherogenic Phenotype and is Prevented by Activating the Nampt-SIRT1 Axis

The Mammalian Target Of Rapamycin And Dna Methyltransferase 1 Axis Mediates Vascular Endothelial Dysfunction In Response To Disturbed Flow

Fatty acid carbon is essential for dNTP synthesis in endothelial cells

PRKAA1/AMPKα1-driven glycolysis in endothelial cells exposed to disturbed flow protects against atherosclerosis

Targeting mechanosensitive endothelial TXNDC5 to stabilize eNOS and reduce atherosclerosis in vivo

Epigenetic Mechanism in Regulation of Endothelial Function by Disturbed Flow: Induction of DNA Hypermethylation by DNMT1

Therapeutic Targeting of Neutrophil Extracellular Traps in Atherogenic Inflammation

Atheroprotective Effects of Methotrexate Via the Inhibition of YAP/TAZ under Disturbed Flow

Hemodynamic Disturbed Flow Induces Differential DNA Methylation of Endothelial Kruppel-Like Factor 4 Promoter in Vitro and in Vivo